Over the last decade, bariatric surgery has come to be recognised for its effects beyond weight loss. The long-term results of the Swedish Obese Subjects (SOS) study have shown an effect on disease risk, morbidity and mortality [1] . Importantly, there are also clear effects on both preventing the onset of diabetes in obese cohorts, and in producing substantial improvements in glucose homeostasis in those with pre-operative diabetes. This considerable effect facilitates the achievement of treatment targets by diabetic individuals with less medication [2] [3] [4] [5] .
Understandably, there is increasing interest in the role of bariatric surgery in the management of type 2 diabetes. Previous discussions focused on remission of diabetes and the tantalising prospect of a 'diabetes cure'. However, we know now that while partial remission rates of diabetes 2 years post-operatively can be impressively high, no procedure has been shown to achieve complete remission in patients with diabetes at 5 years within the setting of a randomised controlled trial (RCT) [2] [3] [4] [5] . Therefore, the focus has rightly shifted towards the concept of surgery as an adjunctive glycaemic therapy for those who cannot meet their treatment targets with non-surgical therapy alone, and how multimodal medical therapies can be used to optimise the long-term outcomes after surgery.
Over the last 4 years, several major RCTs have established the efficacy of bariatric surgery, and specifically Roux-en-Y gastric bypass (RYGB), sleeve gastrectomy and biliopancreatic diversion, in achieving glycaemic control in type 2 diabetes [2] [3] [4] [5] . In this issue of Diabetologia [6] , the findings of the Calorie Reduction Or Surgery: Seeking to Reduce Obesity And Diabetes Study (CROSSROADS) study, comparing the very best non-surgical care with RYGB, now add to these results. In all of the previous studies, medical care in combination with bariatric surgery was more effective than medical therapy alone at achieving glycaemic control. In association with the improvements in glycaemic control, surgical recipients demonstrated improvements in blood pressure and serum lipids. These improvements were greater, and achieved with fewer drugs, than those achieved with medication alone. Most of the beneficial effects in the initial studies were durable for up to 5 years after surgery.
In the CROSSROADS study, intensive lifestyle interventions, including prescribed exercise and dietary plans, were used. The study was very successful in achieving weight loss and reducing markers of metabolic dysfunction, including HbA 1c and fasting insulin concentrations in both arms. However, in keeping with previous studies on the effect of intensive lifestyle interventions on metabolic control in diabetes, and on weight loss, the initial improvements were not sustainable without the addition of surgery. After 6 months the initial improvements achieved in the intensive lifestyle group began to regress towards baseline. By 12 months, the RYGB group had continued improvements that were greater in magnitude than in the lifestyle intervention group.
The CROSSROADS study confirms the results of previous RCTs: medical therapy and lifestyle interventions combined with surgery are more efficacious than medical and lifestyle interventions alone for weight loss and glycaemic control. However, if there was any lingering doubt, the intensity of the intervention in the non-surgical arm of CROSSROADS makes this finding indisputable. The results of this study emphasise that surgery should not be seen as a replacement for medical therapy, and that people with diabetes should continue to be actively treated with proven medical approaches to obtain optimal health.
The participants in the CROSSROADS study had better glycaemic control at baseline (mean HbA 1c 7.5% [59 mmol/mol]) compared with those in previous studies, with HbA 1c levels of 8.5% (69 mmol/mol) in the study by Mingrone et al, 9% (75 mmol/mol) in Surgical Therapy And Medications Potentially Eradicate Diabetes Efficiently (STAMPEDE), and 9.6% (81 mmol/mol) in the Diabetes Surgery Study [2] [3] [4] [5] . The effect size of the improvement in CROSSROADS was also smaller compared with these studies [2] [3] [4] [5] , but surgery was used earlier in the disease process of diabetes, which adds information to the debate as to when surgery should be considered. Many clinicians advocate intervening with surgery at an early stage, in people with shorter durations of diabetes, as they may be more likely to achieve remission and to remain in remission in the long term. This could conceivably yield long-term reductions in micro-and macrovascular risk. The number needed to treat to achieve a benefit depends on whether the outcome is long-term glycaemic control or incidence of the complications of diabetes. Those with higher HbA 1c values for longer pre-operatively, irrespective of the duration of diabetes, have a greater risk of microand macrovascular disease, and may be the group that derives most benefit from surgery as regards diabetic complications, even if patients in that group do not achieve remission of their diabetes.
This raises the question of whether those with more advanced diabetes, including those with microvascular disease, are most suitable for surgery [7] . While the CROSSROADS study does not report data on microvascular outcomes, albumin:creatinine ratios were reduced by surgery in the STAMPEDE and SOS studies, where there were reductions of almost 50% in the incidence of microvascular complications over a follow-up of up to 20 years post-operatively [1, 8] . Bariatric surgery is also associated with a 25% reduction in the incidence of macrovascular disease, such as myocardial infarction, up to 20 years post-operatively [1] . The most rapid improvements after surgery appear to be in those with diabetic kidney disease, in whom surgery can rapidly ameliorate several metabolic disorders that are directly associated with kidney disease, including hyperglycaemia and hypertension [9] . Whether bariatric surgery can prevent the complications of diabetes remains to be proven in RCTs, but evidence to inform this contentious debate could also be explored in long-term follow-up of CROSSROADS and cohorts of similar RCTs.
The suggestion from CROSSROADS [6] is that treating people with diabetes earlier in the disease process may be of benefit. This concept is consistent with that of operating on individuals with a BMI lower than 35 kg/m 2 . This is the minimum limit set by most national guidelines before bariatric surgery is considered. The traditional approach is based on the premise that people with the highest BMIs are most at risk, and therefore the use of 'risky' bariatric surgery can only be justified for the 'heaviest' cohorts. This is now being challenged as BMI alone cannot determine or predict the risk of diabetic complications. Therefore, historical BMI-based criteria can be flawed and if strictly applied may deny access to evidence-based therapies for many people with diabetes. The International Diabetes Federation has recognised this problem and suggest that bariatric surgery could be considered in those with diabetes and a BMI of less than 35 kg/m 2 who cannot meet their treatment targets on medical therapy alone [5] , but many healthcare systems have failed to adopt this approach.
The CROSSROADS study has significantly added to the evidence base supporting the use of bariatric surgery as an adjunct to standard diabetes care. When used in addition to the core elements of good diabetes management, including medical therapy and lifestyle interventions, bariatric surgery is an invaluable therapy. This is especially true for individuals on non-surgical therapy alone who cannot meet their treatment targets. These results are moving clinicians from a crossroads where many were uncertain about the role of bariatric surgery towards accepting the intervention as part of mainstream diabetes care. As we move along this path, a shift away from the glucocentric view of the effects of surgery on diabetes, long held by the bariatric community, will be necessary. Multimodal medical strategies used in conjunction with bariatric surgery can not only treat diabetes, but may also prevent the complications of diabetes. From CROSSROADS we travel forwards towards the next junction armed with greater understanding.
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